The start-up making drugs in space, then sending them to Australia at 30,870km/h
And then the same capsules are returning to terra firma after travelling at 25 times the speed of sound into our atmosphere?
Why, yes ...
And when they return to Earth, they are returning to Australia?
Yes, again.
'It's actually much less futuristic than it sounds,' says Will Bruey, CEO of Varda Industries, the company launching the drug-factory capsules.
'On average three SpaceX Starlink satellites are launched per day, and our spacecraft is simpler, quite frankly, than a Starlink satellite,' he says.
And, while it's early days for California-based Varda, founded in 2021, the pace of launch for these capsules – whose journey takes them from the US, to low earth orbit, to a South Australian testing range for recovery – is expected to increase.
The start-up is attempting to create a viable business of manufacturing drugs in space, where the lack of gravity unlocks the possibility of new, more effective – and more profitable – drug compounds that can't be made on Earth.
Being in space, the limits on the scale of manufacturing are different to an Earth-bound enterprise – both in the molecular quality of what can be produced and, potentially one day, the scale of the production facility.
For now, the company's future depends on how effectively and profitably it can formulate drugs – or at least the most effective primary active pharmaceutical ingredient – in orbit.
When discussing drug production, Bruey compares microgravity (ultra-low gravity in orbit) to the effect that refrigeration has had on drug production since it was invented.
Before refrigeration existed, people would have asked, how could it create value for pharmaceuticals? Today, refrigeration is a fundamental part of drug and vaccine manufacturing, shipping and storage. It reduces the risk of contamination and helps ensure the drugs are effective. Profitable drug manufacturing would be almost unthinkable without it.
One day, space-based drugs may be discussed the same way. 'The way the pharmaceutical industry will think about [Varda] shortly is just another piece of equipment.'
Even the name of the spacecraft – the W in Varda's W-series capsule – unofficially stands for 'Winnebago' (or caravan in American English) used in TV series Breaking Bad, which is itself a story about the remote, compartmentalised cooking up of drugs.
'Instead of going to the desert, we're going to space,' Bruey said.
Likewise, Varda is hauling its equipment to a destination to make its batch, then coming back. 'So that's what we'll be doing. And we'll just be increasing the amount of Winnebagos that are going out to space and back.'
'There's a lot of low-hanging fruit and optimisation to be done in that paradigm.'
Any drug with a formulation improvement worth more than $US200 a gram is viable for Varda to manufacture today. But Varda forecasts it can drive down the cost from $US200 to $US20 'pretty easily by just making our systems more reusable'.
To push lower than that, the company will construct a permanent station with manufacturing equipment that can be used for multiple drugs, Bruey says.
Much of the science around drugmaking in space has been done. There have been numerous experiments on pharmaceuticals, for example, on the International Space Station.
Varda hopes to have a space-made drug in humans by the end of the decade. In an era of sagging productivity, it's worth considering the value of genre-melding new ventures.
The question is: how much demand is there for a service that is new to the world? And on Earth – in Australia – how many re-entries could we see?
Adelaide-based company, Southern Launch, was formed in 2017 as a spaceport operator providing launch services. It has since begun offering orbital re-entry services for customers like Varda.
Their range, at Koonibba in South Australia, enjoys clearer skies with less air traffic than test ranges in the US, giving more flexibility to Varda and other clients, Southern Launch says.
Southern Launch CEO Lloyd Damp said the missions conducted for Varda so far, 'mark an incredible step forward for Australia as the global landing site for re-entries and the in-space manufactured goods the capsules carry.'
Investing in an unproven business model is riskier than investing in say, inner city residential property. But Bruey sees Varda as carving out a niche that can expand as demand grows.
'Basically, there's only four fundamental forces of physics, and gravity is one of them, and we have a knob on [it], and no other company does.' (If you're wondering, the three other forces are: electromagnetism and the strong and weak nuclear forces).
Bruey knows about physics because he studied the subject at Cornell University before founding a couple of companies and working at Elon Musk's SpaceX.
Bruey then met up with Delian Asparouhov, who was looking to invest in a company that could do this work. Asparouhov was looking for someone with Bruey's background and who 'was willing to drop everything and go on this adventure'.
Varda now has backing from Khosla Ventures, Lux Capital, Caffeinated Capital, Founders Fund, and General Catalyst. It has raised $US187 million in a new funding round this month, bringing the total capital raised to $US329 million.
The bet that money can be made by low-orbit manufacturing has caught the attention of SpaceX, which reportedly has plans to get into the space-drug game by manufacturing too.
Elon Musk's company plans to use its massive – and recently unlucky – Starship rocket for the purpose, according to Bloomberg. Sources close to Varda call the report about SpaceX's plan, called Starfall, a 'validation' of Varda's business model.
Like SpaceX, Varda's goal isn't science, it's business: advanced, space-tech business, with the potential to unlock a huge new market that could one day involve large in-orbit factories. The in-space manufacturing market could be worth $US10 billion in five years, according to McKinsey.
But exploiting a fundamental force of physics for profit comes with some hard realities. If you send the capsule into space, you must find a reliable place to recover the spacecraft – closing the loop on the production process.
That's where Australia comes in.
Varda's first craft W-1, launched in June 2023, was due to return in July, but instead got delayed as the company sought permission for the landing in Utah. It remained in orbit for eight months while the details of a new license were resolved between government authorities.
While W-1 was in orbit, Varda reached out to Australia's space industry, looking for reliable space return services.
W-1's February 2024 return coincided with Varda being granted a 'Part 450 re-entry license' from the FAA's Office of Space Transportation, part of a new process to accommodate repeated missions common in commercial space.
Varda now has a FAA license which allows the company to launch and re-enter a craft without spelling out the identical parameters of the mission on repeated applications.
When Varda's W-2 landed in South Australia, Enrico Palermo, head of the Australian Space Agency said it highlighted 'the opportunity for Australia to become a responsible launch and return hub for the global space community, capitalising off the geographic advantages of our expansive continent.'
Unlike crewed missions, which must gently skim into the atmosphere without burning up to bring humans safely home, Varda's missions comes in 'ballistically, as if it's like a missile'.
In that phase, the Winnebagos achieve Mach 25, twenty-five times the speed of sound, or 30,870 kilometres per hour.
Varda has attached a camera to the capsule to capture the dramatic re-entry footage, which looks something like a gas log on overdrive. In space.
The pink glow you see is plasma, Bruey says, from the capsule moving so fast and creating so much heat 'it's literally ripping the molecules in the atmosphere apart and ripping away their electrons'.
'The streaks of what looks like fire is the heat shield 'ablating', that is the little pieces coming off intentionally to take away the heat, shedding it from the spacecraft.'
So far, Varda has created a crystal form of an HIV drug ritonavir in space.
It has research collaborations with large pharma brands, whose names Varda would not give, citing non-disclosure agreements.
W-2 and W-3 landed in February and May 2025 at Koonibba Test Range in South Australia. W-4 is currently in orbit. Varda says it is on track for four missions in 2025 – with plans to expand to a double-capsule mission in 2026. From there, the pace is expected to increase to a weekly pace.
Veteran space industry observer and contributor Brett Biddington says Australia is 'well-suited to support the recovery of payloads from space' with a historical record that is 'unblemished'.
'Whether a viable business can be made just from recovery support is another question,' he says.
He expects that the 'activity will be lumpy and sporadic' and can best thought of as a 'supplementary income stream' to one that is more reliable.
Varda's plan isn't to create a new business alone, but the industry needed to support and grow the enterprise.
With the capsules going up and coming back, we will soon know if Varda is successful.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Perth Now
10 minutes ago
- Perth Now
Industry event raises over $15,000 for vulnerable teens
WA's shipping and logistics community turned out in force on Saturday night for the sixth annual WA International Trade Ball, a sold-out event that raises funds for vulnerable teens dealing with mental health issues. The gala at The Westin Perth drew in more than 300 attendees, from freight forwarders and custom brokers to maritime professionals from across the State. The night raised more than $15,000 for Ruah's Luminos Project, a Northbridge-based residential centre that provides early intervention and support for young people experiencing thoughts of suicide. According to Ruah, the Luminous Project provides peaceful recovery spaces for young people without needing a mental health diagnosis and with referrals being able to be made by anyone. '(The Luminos Project) is supported by trained staff including a clinical psychologist, youth suicide counsellors, peer support workers with lived experience, and support counsellors. It focuses on helping young people build hope, resilience, and practical strategies for their future,' their site says. Spearheaded by shipping industry leaders Sherie Le Brun of Direct Couriers, Emma Cribbin of Navia Freight, and John Park of Freight & Trade Alliance, the event has cemented its place on the WA shipping calendar not just for the glitz and the glam but for its commitment to giving back to the community. Ms Le Brun, who was also the co-organiser of the event, said the community had been awesome. 'It's even more incredible when we work hard to make it a great night and have so many people champion the event year after year,' she said. Mr Park said the shipping industry was proud to be able to support local charities such as Ruah. The funds were raised through raffles, auctions, and donations as guests enjoyed live entertainment and fine dining.


Perth Now
40 minutes ago
- Perth Now
Investment bank to face heat over climate commitments
Australia's largest investment bank will be in activists' sights when shareholders gather at its global headquarters for its annual general meeting. Environmental group Market Forces plans to have a four-metre-tall mock gas flare outside Macquarie Group's new Martin Place offices in Sydney on Thursday morning, representing the bank's financing of climate pollution. At the meeting Macquarie faces its first climate-focused shareholder resolution calling on the $86 billion company to outline how its financing for fossil fuel projects is aligned with its net-zero commitments. Activists say they're concerned about Macquarie's commitment to global climate goals after the bank followed US peers JPMorgan, Citi and Bank of America in exiting the Net Zero Banking Alliance in February, not long after President Donald Trump took office. Macquarie has more than doubled its financing for oil and gas in the past two years, Market Forces says. "Macquarie's reputation as a green financial institution is completely at odds with its investments in one of Australia's biggest new gas developments," said Market Forces policy analyst Morgan Pickett, referring to its financing of a $100 million gas fracking project in the Northern Territory's Beetaloo Basin. Macquarie in late 2024 provided the funding for two of the gas companies most active in the Basin, Beetaloo Energy Australia and Tamboran Resources. Australia's Department of Industry, Science and Resources says Beetaloo has the potential to rival the world's best gas projects, and developing it could create thousands of jobs and drive significant economic growth in the territory. Activists say moving ahead with another gas project is irresponsible as the planet tips further into a climate emergency. "As a climate scientist, I'm appalled that Macquarie Group is claiming to be green yet is lending to companies blasting ahead with new gas projects adding to irreversible global warming," Lesley Hughes, climate change scientist and emerita professor of biology, said in a statement provided by Market Forces. Macquarie is recommending shareholders reject the climate resolution, which asks the bank to disclose its exposure to fossil fuel companies and detail its approach for funding them in light of its goal of net-zero emissions by 2050. Macquarie says the science behind climate change is "clear and unequivocal" but it believes in "a managed, orderly and just transition". "This means supporting carbon-intensive industries and companies including those in the oil/gas, electricity, agriculture, mining, transport and waste sectors to decarbonise, while protecting the vital services and jobs that our communities rely on," Macquarie said. Market Forces says four global investors have backed the shareholder resolution: the pension funds of New York City, the UK's Church of England and the largest private pension fund in Norway, as well as Melbourne-based fund manager ELM Responsible Investments.

AU Financial Review
8 hours ago
- AU Financial Review
An onsen and a tea house: What to expect from this new Melbourne tower
Melbourne-based developer Holder East is launching a new hotel and residential project in Southbank, drawing design inspiration from Japanese wellness rituals by offering its own 'onsen' and private tea house. Holder East hopes to break ground in February for the 48-storey tower at 526 Clarendon Street with the name Sento – a word that means bathhouse in Japanese. It will have 140 apartments ranging from one, two and three bedrooms and 10 penthouses.